Recursion Pharmaceuticals (RXRX) Other Operating Expenses (2022 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Other Operating Expenses came in at $12.5 million in Q1 2026, down 42.78% YoY from $21.8 million in Q1 2025, and down 12.5% on a QoQ basis from $14.3 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Other Operating Expenses (2022 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 5 years of Other Operating Expenses data on file, last reported at $12.5 million in Q1 2026.
- Quarterly Other Operating Expenses fell 42.78% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.6 million (up 10.22% YoY) and the FY2025 annual result came in at $71.0 million, up 56.84% from the prior year.
- Other Operating Expenses declined to $12.5 million in Q1 2026, from $14.3 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $21.8 million in Q1 2025 to a low of $7.8 million in Q1 2022.
- A 5-year average of $12.9 million and a median of $12.4 million in 2023 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2025 — Other Operating Expenses jumped 119.17% — and 2026, when it slumped 42.78%.
- Tracing RXRX's Other Operating Expenses over 5 years: stood at $10.8 million in 2022, then fell by 8.85% to $9.9 million in 2023, then climbed by 29.48% to $12.8 million in 2024, then increased by 11.58% to $14.3 million in 2025, then fell by 12.5% to $12.5 million in 2026.
- The last three Other Operating Expenses figures came in at $12.5 million (Q1 2026), $14.3 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.49 Mn |
| Mar 31, 2026 | 12.49 Mn |
| Dec 31, 2025 | 14.28 Mn |
| Sep 30, 2025 | 14.69 Mn |
| Jun 30, 2025 | 20.16 Mn |
| Mar 31, 2025 | 21.83 Mn |
| Dec 31, 2024 | 12.79 Mn |
| Sep 30, 2024 | 12.08 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 11.17 Mn |
| Dec 31, 2023 | 9.88 Mn |
| Sep 30, 2023 | 10.88 Mn |
| Jun 30, 2023 | 9.38 Mn |
| Mar 31, 2023 | 12.45 Mn |
| Dec 31, 2022 | 10.84 Mn |
| Sep 30, 2022 | 15.41 Mn |
| Jun 30, 2022 | 14.23 Mn |
| Mar 31, 2022 | 7.80 Mn |